WO2008014035A3 - Modulation of nkg2d and method for treating or preventing solid organ allograft rejection - Google Patents
Modulation of nkg2d and method for treating or preventing solid organ allograft rejection Download PDFInfo
- Publication number
- WO2008014035A3 WO2008014035A3 PCT/US2007/068348 US2007068348W WO2008014035A3 WO 2008014035 A3 WO2008014035 A3 WO 2008014035A3 US 2007068348 W US2007068348 W US 2007068348W WO 2008014035 A3 WO2008014035 A3 WO 2008014035A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nkg2d
- treating
- cells
- allograft rejection
- solid organ
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D. The present application also relates to method for treating or preventing solid organ allograft rejection, the method comprising administering an agent that reduces ligand-induced NKG2D activation of cells (such as an antibody that binds NKG2D) and an inhibitor of lymphocyte co-stimulation to a subject in need thereof (such as CTLA4-Ig or LEA29Y)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83338306P | 2006-07-25 | 2006-07-25 | |
US60/833,383 | 2006-07-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008014035A2 WO2008014035A2 (en) | 2008-01-31 |
WO2008014035A3 true WO2008014035A3 (en) | 2008-04-03 |
Family
ID=38969958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/068348 WO2008014035A2 (en) | 2006-07-25 | 2007-05-07 | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008014035A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2769409A1 (en) * | 2009-08-17 | 2011-02-24 | The Penn State Research Foundation | Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes |
WO2013032943A1 (en) * | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Methods and compositions for the treatment of respiratory conditions via nkg2d inhibition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094202A2 (en) * | 2001-05-23 | 2002-11-28 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
WO2005097160A2 (en) * | 2004-04-05 | 2005-10-20 | The Regents Of The University Of California | Modulation of nkg2d |
WO2006108035A1 (en) * | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
-
2007
- 2007-05-07 WO PCT/US2007/068348 patent/WO2008014035A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094202A2 (en) * | 2001-05-23 | 2002-11-28 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
WO2005097160A2 (en) * | 2004-04-05 | 2005-10-20 | The Regents Of The University Of California | Modulation of nkg2d |
WO2006108035A1 (en) * | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
Non-Patent Citations (11)
Title |
---|
ADAMS A B ET AL: "CALCINEURIN INHIBITOR-FREE CD28 BLOCKADE-BASED PROTOCOL PROTECTS ALLOGENEIC ISLETS IN NONHUMAN PRIMATES", DIABETES, NEW YORK, NY, US, vol. 51, no. 2, February 2002 (2002-02-01), pages 265 - 270, XP008054843, ISSN: 0012-1797 * |
ADAMS A B ET AL: "Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 174, no. 1, 1 January 2005 (2005-01-01), pages 542 - 550, XP002393472, ISSN: 0022-1767 * |
HANCOCK W W ET AL: "Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 15, no. 5, October 2003 (2003-10-01), pages 479 - 486, XP004457002, ISSN: 0952-7915 * |
HATTORI RYOHEI ET AL: "[Renal transplantation]", NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE NOV 2005, vol. 63, no. 11, November 2005 (2005-11-01), pages 1950 - 1955, XP009095381, ISSN: 0047-1852 * |
LARSEN C P ET AL: "Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties", AMERICAN JOURNAL OF TRANSPLANTATION, BLACKWELL MUNKSGAARD,, DK, vol. 5, no. 3, March 2005 (2005-03-01), pages 443 - 453, XP002393471, ISSN: 1600-6135 * |
LI ET AL: "CTLA4-Ig-Based Conditioning Regimen to Induce Tolerance to Cardiac Allografts", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 136, no. 2, 15 November 2006 (2006-11-15), pages 238 - 246, XP005741054, ISSN: 0022-4804 * |
MAIER STEFAN ET AL: "Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice", NATURE MEDICINE, vol. 7, no. 5, May 2001 (2001-05-01), pages 557 - 562, XP002467594, ISSN: 1078-8956 * |
MCNERNEY M E ET AL: "Role of natural killer cell subsets in cardiac allograft rejection.", AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS MAR 2006, vol. 6, no. 3, March 2006 (2006-03-01), pages 505 - 513, XP002467595, ISSN: 1600-6135 * |
OGASAWARA KOUETSU ET AL: "NKG2D blockade prevents autoimmune diabetes in NOD mice", IMMUNITY, CELL PRESS, US, vol. 20, no. 6, June 2004 (2004-06-01), pages 757 - 767, XP002359222, ISSN: 1074-7613 * |
VINCENTI F ET AL: "COSTIMULATION BLOCKADE WITH BELATACEPT IN RENAL TRANSPLANTATION", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 8, 25 August 2005 (2005-08-25), pages 770 - 781, XP009070530, ISSN: 1533-4406 * |
WEBER C J ET AL: "CTLA4-IG PROLONGS SURVIVAL OF MICROENCAPSULATED RABBIT ISLET XENOGRAFTS IN SPONTANEOUSLY DIABETIC NOD MICE", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 28, no. 2, April 1996 (1996-04-01), pages 821 - 823, XP008054845, ISSN: 0041-1345 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008014035A2 (en) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005097160A3 (en) | Modulation of nkg2d | |
NO20091841L (en) | Antibodies to Lymphotoxin-alpha | |
BRPI0506726A (en) | specifically for m-csf and yours this | |
WO2007130642A3 (en) | Modulation of nkg2d | |
EP2500362A3 (en) | Humanized antibodies against TL1A | |
TW200605907A (en) | Preventing autoimmune disease | |
WO2006118772A3 (en) | Fcrn antibodies and uses thereof | |
MEP7408A (en) | Peptides that block the binding of igg to fcrn | |
WO2006012373A3 (en) | Combination therapies of hmgb and complement inhibitors against inflammation | |
EP2330120A3 (en) | Binding moieties based on Shark IgNAR domains | |
MY159517A (en) | A monoclonal antibody and a method thereof | |
WO2006122257A3 (en) | Nebulization of monoclonal antibodies for treating pulmonary diseases | |
WO2007145947A3 (en) | High back pressure filter for removing non-water component(s) from water, and methodology | |
WO2007033230A3 (en) | Anti-cd3 antibody formulations | |
WO2008116219A3 (en) | Uses of monoclonal antibody 8h9 | |
WO2001098357A3 (en) | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations | |
WO2008060705A8 (en) | Anti-dll4 antibodies and methods using same | |
NO20092743L (en) | Antibodies to CD200R | |
GB0711327D0 (en) | Diagnostic method | |
WO2007111938A3 (en) | Inflammation-inhibitory serum factors and uses thereof | |
WO2007059300A3 (en) | Anti-alk antagonist and agonist antibodies and uses thereof | |
WO2008008348A3 (en) | Method and compositions for treating stroke with fever | |
WO2005079515A3 (en) | Conformation specific antibodies | |
WO2006029220A3 (en) | Combination therapy with anti-ctla4 and anti-4-1bb antibodies | |
WO2019202399A8 (en) | Antibodies for chelated radionuclides and clearing agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07783369 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07783369 Country of ref document: EP Kind code of ref document: A2 |